ClinicalTrials.gg
CompletedNCT03197766Updated Mar 2, 2022Results posted

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

A Phase 3 interventional study of BMN 111 and Placebo in Achondroplasia, sponsored by BioMarin Pharmaceutical. Completed at 24 sites in 7 countries. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2016, registered May 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
5 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Achondroplasia by BioMarin Pharmaceutical — 2 open to participants now, 6 under way, 2 of them phase 3. Achondroplasia · BioMarin Pharmaceutical.

Enrollment
2nd of 10
121 · median 74
Started
2016
with 1 other
Phase 3
2 of 14
none open now
Registered
5th of 14
by date

Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2016, is one of 2 in phase 3, and was the 5th registered.

Achondroplasia

47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.

Browse Achondroplasia studies →

Open to participants now

2 of the 14 studies in Achondroplasia by BioMarin Pharmaceutical are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 5 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Achondroplasia by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia.

Read the detailed description

This is a Phase 3 randomized, placebo-controlled, double-blind multicenter study with approximately 110 subjects, aged 5 to \< 18 years old. Subjects with documented Achondroplasia confirmed by genetic testing will have been enrolled in Study 111-901 for at least a 6-month period immediately before entering into the 111-301 study. Eligible subjects will be randomly assigned to one of two treatment groups: placebo or BMN 111 at 15 μg/kg. The route of administration is subcutaneous injection and the frequency is daily.

03

Conditions studied

  • Achondroplasia

Keywords

  • Achondroplasia
  • Dwarfism
  • Bone Diseases
  • Bone Diseases, Developmental
  • ACH
  • Natriuretic Peptide, C-Type
  • Musculoskeletal Diseases
  • Natriuretic Agents
  • Physiological Effects of Drugs
  • Skeletal Dysplasias
  • Genetic Diseases, Inborn
  • Osteochondrodysplasias
04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parent(s) or guardian(s) consent
  • 5 to \< 18 years old
  • ACH, documented and confirmed by genetic testing
  • At least a 6-month period of pretreatment growth assessment in Study 111-901 before study entry
  • If sexually active, willing to use a highly effective method of
  • Ambulatory and able to stand without assistance

Exclusion criteria

Exclusion criteria:

  • Hypochondroplasia or short stature condition other than ACH
  • Have any of the following:

    • Hypothyroidism or hyperthyroidism
    • Insulin-requiring diabetes mellitus
    • inflammatory disease
    • Inflammatory bowel disease
    • Autonomic neuropathy
  • History of any of the following:

    • Renal insufficiency defined as serum creatinine > 2 mg/dL
    • Chronic anemia
    • Baseline systolic blood pressure (BP) \< 70 millimeters of mercury (mm Hg) or recurrent symptomatic hypotension (defined as episodes of low BP generally accompanied by symptoms ie, dizziness, fainting) or recurrent symptomatic orthostatic hypotension
    • Cardiac or vascular disease

      • Have a finding or arrhythmia on screening (ECG) that indicates abnormal cardiac function or conduction or Fridericias corrected -F > 450 msec
  • Have an unstable condition likely to require surgical intervention during the study (including progressive cervical medullary compression or severe untreated sleep apnea)
  • Decreased growth velocity (\< 1.5 cm/yr) over a period of 6 months or evidence of growth plate closure (proximal tibia, distal femur)
  • Treated with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids in the previous 6 months or treatment greater than 6 months at any time
  • Greater than 1 month treatment with oral (low-dose ongoing inhaled steroid for asthma, or intranasal steroids, are acceptable) in the previous 12 months
  • Planned or expected to have limb-lengthening surgery during the study period. Subjects with previous limb- lengthening surgery may enroll if surgery occurred at least 18 months prior to the study and healing is complete without sequelae.
  • Planned or expected bone-related surgery (ie. surgery involving disruption of bone cortex, excluding tooth extraction), during the study period. Subjects with previous bone-related surgery may enroll if surgery occurred at least 6 months prior to the study and healing is complete without sequelae.
  • Had a fracture of the long bones or spine within 6 months prior to screening
  • History of severe untreated sleep apnea
  • New initiation of sleep apnea treatment (e.g. CPAP or sleep apnea-mitigating surgery) in the previous 2 months prior to screening
  • History of hip surgery or hip dysplasia atypical for achondroplastic subjects
  • History of clinically significant hip injury in the 30 days prior to screening
  • History of slipped capital femoral epiphysis or avascular necrosis of the femoral head
  • Abnormal findings on baseline clinical hip exam or imaging assessments that are determined to be clinically significant
  • Concurrent disease or condition that would interfere with study participation or safety evaluations, for any reason
  • Condition or circumstance that places the subject at high risk for poor treatment compliance or for not completing the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Active BMN 111

    Daily subcutaneous injection of 15 micrograms per kilogram BMN111

    Drug: BMN 111

  • Placebo comparator
    Placebo

    Daily subcutaneous injection of placebo

    Drug: Placebo

Interventions

  • Subcutaneous injection of 15 μg/kg of BMN 111 daily

    Also known as: Vosoritide, Modified recombinant human C-type natriuretic peptide

  • DrugPlacebo

    Subcutaneous injection of 15 μg/kg of placebo daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Annualized Growth Velocity (AGV) at Week 52

    AGV at a Post-baseline Visit is defined as \[(Height at Post-baseline Visit - Height at Baseline)/(Date of Post-baseline Visit - Date of Baseline Assessment)\] x 365.25 AGV at Baseline is defined as \[(Height at Baseline - last height measurement in Study 111-901 at least 6 months prior to Baseline)/(Date of Baseline Assessment - Date of last height measurement in Study 111-901 at least 6 months prior to Baseline)\] x 365.25

    Time frame: At Baseline and Week 52

Secondary outcomes

  1. Change From Baseline in Height Z-score at Week 52

    Z-Scores were derived using age-sex specific reference data (means and SDS) for average stature children per the Centers for Disease Control and Prevention. A height Z score of 0 would indicate that the subject's height is equal to the mean height for the average stature population of the same sex and age. A positive height Z score indicates that the subjects height is above the mean height for the average stature population of the same sex and age, whilst a negative height Z score indicates that the subjects height is below the mean height for the average stature population of the same sex and age. To conclude if the height Z score increases then this means the height deficit has decreased.

    Time frame: At baseline and Week 52

  2. Change From Baseline in Upper to Lower Segment Body Ratio at Week 52

    Evaluate change from baseline in mean upper:lower segment body ratio in subjects treated with BMN 111 compared with control subjects in the placebo group at 52 weeks

    Time frame: At baseline and Week 52

  3. Summary of Subjects Experiencing Adverse Events (AEs) During Treatment

    AEs with onset or worsening after the initiation of study drug and up to 30 days after study drug discontinuation were included. serious adverse event (SAE)

    Time frame: Up to Week 56

07

Results

Posted Mar 2, 2022

Participant flow

This was a multi-centre study conducted by 24 principal investigators at 24 study centers in 7 countries

Participant flow — Overall Study
MilestoneBMN 111 - 15 μg/kgPlacebo
Started6061
Completed5861
Not completed20
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryChange From Baseline in Annualized Growth Velocity (AGV) at Week 52

AGV at a Post-baseline Visit is defined as \[(Height at Post-baseline Visit - Height at Baseline)/(Date of Post-baseline Visit - Date of Baseline Assessment)\] x 365.25 AGV at Baseline is defined as \[(Height at Baseline - last height measurement in Study 111-901 at least 6 months prior to Baseline)/(Date of Baseline Assessment - Date of last height measurement in Study 111-901 at least 6 months prior to Baseline)\] x 365.25

Time frame:
At Baseline and Week 52
Reported as:
Least squares mean · cm/year
Change From Baseline in Annualized Growth Velocity (AGV) at Week 52
cm/yearBMN 111 - 15 μg/kgPlacebo
Change From Baseline in Annualized Growth Velocity (AGV) at Week 521.71 (1.40 to 2.01)0.13 (-0.18 to 0.45)
Statistical analysis
  • BMN 111 - 15 μg/kg vs Placebo · ANCOVA · p = < 0.0001 (Confirmatory statistical testing controlling for the Type I error rate was performed on the primary analysis for the primary endpoint.)Two subjects in the BMN 111 group discontinued from the study before Week 52. The values for these 2 subjects were imputed for this analysis.
SecondaryChange From Baseline in Height Z-score at Week 52

Z-Scores were derived using age-sex specific reference data (means and SDS) for average stature children per the Centers for Disease Control and Prevention. A height Z score of 0 would indicate that the subject's height is equal to the mean height for the average stature population of the same sex and age. A positive height Z score indicates that the subjects height is above the mean height for the average stature population of the same sex and age, whilst a negative height Z score indicates that the subjects height is below the mean height for the average stature population of the same sex and age. To conclude if the height Z score increases then this means the height deficit has decreased.

Time frame:
At baseline and Week 52
Reported as:
Least squares mean · Z-Score
Change From Baseline in Height Z-score at Week 52
Z-ScoreBMN 111 - 15 μg/kgPlacebo
Change From Baseline in Height Z-score at Week 520.27 (0.18 to 0.36)-0.01 (-0.10 to 0.09)
Statistical analysis
  • BMN 111 - 15 μg/kg vs Placebo · ANCOVA · p = < 0.0001 (Confirmatory statistical testing controlling for the Type I error rate was performed on the primary analyses for the two key secondary endpoints.)Missing assessments at Week 52 were imputed
SecondaryChange From Baseline in Upper to Lower Segment Body Ratio at Week 52

Evaluate change from baseline in mean upper:lower segment body ratio in subjects treated with BMN 111 compared with control subjects in the placebo group at 52 weeks

Time frame:
At baseline and Week 52
Reported as:
Least squares mean · Ratio
Change From Baseline in Upper to Lower Segment Body Ratio at Week 52
RatioBMN 111 - 15 μg/kgPlacebo
Change From Baseline in Upper to Lower Segment Body Ratio at Week 52-0.03 (-0.06 to 0.00)-0.02 (-0.05 to 0.01)
Statistical analysis
  • BMN 111 - 15 μg/kg vs Placebo · ANCOVA · p = = 0.506 (Confirmatory statistical testing controlling for the Type I error rate was performed on the primary analyses for the two key secondary endpoints.)Missing assessments at Week 52 were imputed
SecondarySummary of Subjects Experiencing Adverse Events (AEs) During Treatment

AEs with onset or worsening after the initiation of study drug and up to 30 days after study drug discontinuation were included. serious adverse event (SAE)

Time frame:
Up to Week 56
Reported as:
Number · participants
Summary of Subjects Experiencing Adverse Events (AEs) During Treatment
participantsBMN 111 - 15 μg/kgPlacebo
Subjects with any AE5960
Subjects with any SAE34
Subjects with any treatment-related AE5351
Subjects who died00

Adverse events

Collected over Up to Week 56. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMN 111 - 15 μg/kg0/60 (0%)3/60 (5%)59/60 (98.3%)
Placebo0/61 (0%)4/61 (6.6%)60/61 (98.4%)
Most frequent serious events
Most frequent serious events
EventBMN 111 - 15 μg/kgPlacebo
InfluenzaInfections and infestations1/600/61
Radius fractureInjury, poisoning and procedural complications1/600/61
Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders1/601/61
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders1/600/61
AppendicitisInfections and infestations0/601/61
DyspnoeaRespiratory, thoracic and mediastinal disorders0/601/61
Intracranial pressure increasedNervous system disorders0/601/61
Spinal cord compressionNervous system disorders0/601/61
Most frequent other events
Showing 10 of 177
Most frequent other events
EventBMN 111 - 15 μg/kgPlacebo
Injection site reactionGeneral disorders44/6029/61
Injection site erythemaGeneral disorders41/6040/61
Injection site swellingGeneral disorders23/606/61
NasopharyngitisInfections and infestations16/6018/61
VomitingGastrointestinal disorders16/6012/61
HeadacheNervous system disorders14/6016/61
PyrexiaGeneral disorders10/6013/61
Upper respiratory tract infectionInfections and infestations8/6010/61
ArthralgiaMusculoskeletal and connective tissue disorders9/604/61
Injection site urticariaGeneral disorders8/602/61

Baseline characteristics

Analysis were performed on the Full Analysis Set (FAS) which included all randomized subjects with a signed informed consent.

Age, Continuous
Age, Continuous(years)BMN 111 - 15 μg/kgPlaceboTotal
Mean8.35 ± 2.439.06 ± 2.478.71 ± 2.47
Sex: Female, Male
Sex: Female, Male(Participants)BMN 111 - 15 μg/kgPlaceboTotal
Female292857
Male313364
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMN 111 - 15 μg/kgPlaceboTotal
Hispanic or Latino167
Not Hispanic or Latino5955114
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BMN 111 - 15 μg/kgPlaceboTotal
Race — White454186
Race — Asian-Other7916
Race — Asian-Japanese347
Race — Multiple257
Race — Black or African American325
Annualized Growth Velocity (AGV)
Annualized Growth Velocity (AGV)(cm/year)BMN 111 - 15 μg/kgPlaceboTotal
Mean4.26 ± 1.534.06 ± 1.204.16 ± 1.37
Height Z-Score
Height Z-Score(Z-score)BMN 111 - 15 μg/kgPlaceboTotal
Mean-5.13 ± 1.11-5.14 ± 1.07-5.13 ± 1.09
Upper to Lower Body Segment Ratio
Upper to Lower Body Segment Ratio(Ratio)BMN 111 - 15 μg/kgPlaceboTotal
Mean1.98 ± 0.202.01 ± 0.212.00 ± 0.20
08

Study locations

24 sites
  • Children's Hospital & Research Center Oakland
    Oakland, California 94609, United States
  • Harbor - UCLA Medical Center
    Torrance, California 90509, United States
  • Alfred I. duPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Emory University
    Decatur, Georgia 30033, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Missouri
    Columbia, Missouri 65201, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Medical College of Wisconsin, Children's Hospital
    Milwaukee, Wisconsin 53226, United States
  • The Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
  • Murdoch Children's Research Institute
    Parkville, Victoria 3052, Australia
  • Otto-von-Guericke Universitaet, Universitaetskinderklinik
    Magdeburg, 39120, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Osaka University Hospital
    Osaka, Japan
  • Saitama Children's Medical Center
    Saitama, Japan
  • Tokushima University Hospital
    Tokushima, Japan
  • Institut Catala de Traumatologica I Medicina de l'Esport
    Barcelona, 08028, Spain
  • Hospital Sant Joan de Deu
    Barcelona, 08950, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, 29010, Spain
  • Acibadem University School of Medicine
    Istanbul, 34752, Turkey
  • Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital
    London, SE1 9RT, United Kingdom
  • Sheffield Children's NHS Foundation Trust
    Sheffield, S10 2TH, United Kingdom
09

References and documents

Publications

  • Chan ML, Qi Y, Larimore K, Cherukuri A, Seid L, Jayaram K, Jeha G, Fisheleva E, Day J, Huntsman-Labed A, Savarirayan R, Irving M, Bacino CA, Hoover-Fong J, Ozono K, Mohnike K, Wilcox WR, Horton WA, Henshaw J. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. Clin Pharmacokinet. 2022 Feb;61(2):263-280. doi: 10.1007/s40262-021-01059-1. Epub 2021 Aug 25. PubMed 34431071 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Oct 2019, 34 months.

Results were first posted in Mar 2022, 2 years 4 months after primary completion. A results delay was requested in May 2020.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2017
First posted
Jun 23, 2017
StartActual
Dec 12, 2016
Primary completionActual
Oct 30, 2019
CompletionActual
Oct 30, 2019
Results delay requested
May 13, 2020
Results first posted
Mar 2, 2022
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03197766
Responsible party
Sponsor
First posted
Jun 23, 2017
Start date
Dec 12, 2016
Primary completion
Oct 30, 2019
Completion
Oct 30, 2019
Results posted
Mar 2, 2022
Last update
Mar 2, 2022

Study contacts

Medical Director, MD
study director · BioMarin Pharmaceutical

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vosoritide

Start the discussion